# EDGAR Filing Document

**Accession Number:** 0001817229
**File Stem:** 0001193125-25-261723
**Filing Date:** 2025-11
**Character Count:** 12698
**Document Hash:** b410b426f45881de7764f8aaa3c0987b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-261723.hdr.sgml**: 20251103

**ACCESSION NUMBER**: 0001193125-25-261723

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251102

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251103

**DATE AS OF CHANGE**: 20251103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vor Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001817229
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811591163
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39979
- **FILM NUMBER:** 251442175

**BUSINESS ADDRESS:**
- **STREET 1:** 500 BOYLSTON STREET
- **STREET 2:** SUITE 1350
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 617-655-6580

**MAIL ADDRESS:**
- **STREET 1:** 500 BOYLSTON STREET
- **STREET 2:** SUITE 1350
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** November 02, 2025<br>

------

VOR BIOPHARMA INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-39979 | 81-1591163 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 500 Boylston Street, Suite 1350 |  |  |
| Boston**,** Massachusetts |  | 02116 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 617 655-6580<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | VOR | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 2, 2025 (the "Effective Date"), Vor Biopharma Inc. (the "Company") and Dr. Qing Zuraw, the Company's Chief Development Officer, entered into an amendment (the "Employment Agreement Amendment") to Dr. Zuraw's employment agreement with the Company dated July 17, 2025 (the "Employment Agreement"). The Employment Agreement Amendment provides that (i) in addition to the other severance benefits set forth in the Employment Agreement, in the event Dr. Zuraw is terminated by the Company without cause, Dr. Zuraw will be entitled to a pro-rated portion of her 2025 target bonus and, if applicable, a pro-rated portion of her 2026 target bonus, payable in a lump sum, and (ii) if Dr. Zuraw resigns for any reason after December 31, 2025, she will be entitled to the same severance benefits as are payable in the event of a termination by the Company without cause. The Employment Agreement Amendment is effective for five months following the Effective Date.

The foregoing summary of the Employment Agreement Amendment is not complete and is qualified in its entirety by reference to the full text of the Employment Agreement Amendment, a copy of which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

## Item 7.01 Regulation FD Disclosure.
On November 3, 2025, the Company issued a press release announcing the appointment of Dr. Jeremy Sokolove as Chief Medical Officer, a copy of which is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| 99.1 | [<u>Press Release dated November 3, 2025.</u>](vor-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **Vor Biopharma Inc.** |
| Date: | November 3, 2025 | By:  | /s/ Jean-Paul Kress |
|  |  |  | Name: Jean-Paul Kress<br>Title: Chief Executive Officer |

---

------

## Exhibit 99.1

![img246614764_0.jpg](img246614764_0.jpg)

**Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer**

**BOSTON, Mass., November 3, 2025 (GLOBE NEWSWIRE)** — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Dr. Sokolove brings more than two decades of clinical and translational experience in rheumatology and autoimmune disease research and development to the company's leadership team.

"We are thrilled to welcome Jeremy to Vor Bio," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "His deep clinical expertise as a rheumatologist, coupled with his strong track record in industry and as a thought leader in autoimmune and inflammatory disease clinical research, makes him a perfect fit to drive our clinical strategy. With Jeremy on board, we are more confident than ever in advancing our dual BAFF/APRIL approach toward meaningful impact for patients."

Most recently, Dr. Sokolove served as Chief Medical Officer In-Residence at Roivant Sciences where he led strategic assessment and in-licensing of novel therapeutic opportunities while providing operational leadership, clinical guidance, and translational expertise across Roivant's emerging and established portfolio companies. Before that, he was Chief Medical Officer at Odyssey Therapeutics, leading the transition of the company to a clinical-stage biotechnology organization focused on next-generation immunomodulators for autoimmune and inflammatory diseases. Earlier, Dr. Sokolove was Senior Vice President and Head of Clinical Pharmacology and Experimental Medicine at GSK, where he led early and translational development across the specialty pharma portfolio, and previously Head of Immunology Translational Science at AbbVie, directing early-phase clinical programs and building portfolio-wide translational medicine strategy. He began his career on the faculty at Stanford University School of Medicine as a practicing rheumatologist and primary investigator, where his research focused on biomarker discovery and immune-mediated disease mechanisms.

Dr. Sokolove has practiced extensively as an internist and rheumatologist, treating patients and leading clinical research programs focused on autoimmune and inflammatory disorders. He has published extensively in the fields of immunology and rheumatology, contributing to the understanding of immune-mediated disease mechanisms. His academic credentials include board certification in internal medicine and rheumatology, and he holds an MD from the Boston University School of Medicine.

"I am joining Vor Bio because I see strong scientific and clinical potential in the BAFF/APRIL pathways to precisely modulate the core mechanisms underlying autoimmune diseases," said Dr. Sokolove. "Telitacicept represents a differentiated, near-term opportunity to meaningfully improve outcomes for patients with limited therapeutic options or those who depend on broad immunosuppression. I look forward to working with the team to execute a global clinical development program for Telitacicept that could translate into a therapy that can make a real difference in the lives of patients."

<br>**About Vor Bio**

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion

------

![img246614764_0.jpg](img246614764_0.jpg)

protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "aim," "anticipate," "can," "continue," "could," "design," "enable," "expect," "initiate," "intend," "may," "on-track," "ongoing," "plan," "potential," "should," "target," "update," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio's statements regarding the potential benefits of telitacicept and the dual BAFF/APRIL approach, including the potential of the BAFF/APRIL pathways to precisely modulate the core mechanisms underlying autoimmune diseases, and telitacicept's potential to meaningfully improve outcomes for patients with limited therapeutic options or those who depend on broad immunosuppression and to make a real difference in the lives of patients.

Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including the data for our product candidates may not be sufficient for obtaining regulatory approval to commercialize products; we may not be able to execute our business plans, including meeting our planned clinical and regulatory milestones and timelines, and possible limitations of financial and other resources. These and other risks are described in greater detail under the caption "Risk Factors" included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission.

Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

**Media & Investor Contacts:**<br>Carl Mauch

cmauch@vorbio.com

Sarah Spencer

investors@vorbio.com

------